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Abstract
A COMPARISON OF THE RATE OF ARTERIOSCLEROSIS IN PATIENTS WITH
THE MARFAN SYNDROME AND THE GENERAL POPULATION. Biren P. Modi
and John A. Elefteriades. Section of Cardiothoracic Surgery, Department of Surgery,
Yale University School of Medicine, New Haven, CT.

The purpose of this study was to determine the prevalence of arteriosclerosis in patients
with the Marfan syndrome in comparison to control individuals from the general
population. The study arm consisted of 8 patients with Marfan syndrome who had
available preoperative computed tomography (CT) scans of the chest without intravenous
contrast. The control arm consisted of 8 age and gender matched patients who also had
available CT scans of the chest. The CT scans were evaluated for the presence of
calcium in the thoracic aorta and the coronary arteries using a semi-quantitative scale
score of 0-3 for each artery. For all patients, a thorough chart review was conducted to
search for body mass index and any history of hypertension, hypercholesterolemia,
diabetes, prior stroke, prior myocardial infarction, or smoking. Though the differences
were not significant, the Marfan group was younger, leaner, more likely to qualify as
hypertensive due to beta-blocker administration, and less likely to be diabetic. The mean
aortic calcium scores for Marfan patients and control patients were 0.000 and 0.125,
respectively (p=0.5). The mean coronary calcium scores for Marfan patients and control
patients were 0.000 and 0.125, respectively (p=0.5). These results suggest that some
trends do exist which could indicate that and explain why Marfan patients have less
advanced arteriosclerosis. Future studies will bear out these trends.
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Introduction

Background on Arteriosclerosis

Definition

Arteriosclerosis, literally translated as the hardening of arteries, is a broad term
encompassing several disease states within the arterial circulation which have in common
the thickening and loss of elasticity of the arterial wall. The majority of cases of
arteriosclerosis consist of atherosclerosis, the presence of atheromatous plaques within
the vessel walls of large elastic arteries (e.g., aorta) and medium-sized muscular arteries
(e.g., coronary arteries) (1-3). In addition, arteriosclerosis may include Monckeberg
calcification of the arterial media, which can occur in conjunction with advanced
atherosclerosis, and arteriolosclerosis, which is a similar process involving the smaller
arterioles of the arterial system (2). The most clinically significant, and the pattern which
is under discussion in this study, is atherosclerosis.

Pathophysiology

There has been a tremendous growth in the understanding of the mechanisms
underlying atherosclerosis in the past decades, but many uncertainties still exist. It is
now generally accepted that atherosclerosis is a dynamic process which evolves through
the interplay of many factors. These factors include the endothelial and smooth muscle
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cells of the arterial wall, inflammatory cells and molecular mediators from the
circulation, and the extracellular matrix. The following is a brief description of the
macroscopic evolution of atherosclerosis and the microscopic players in the process.

Atherosclerosis is a generalized process involving many arterial territories,
including the coronary circulation, the head vessels, the aorta, and the peripheral
circulation (1, 4-7). This fact is useful in understanding the pathophysiology of the
process as well as in applying techniques for molecular study, imaging, and therapy.
Since the risk factors for atherosclerotic disease are the same regardless of location, it is a
natural extension that the mechanisms of pathogenesis are similar in all vascular
territories and that treatment or prevention for one clinical manifestation would likewise
treat and prevent all atherosclerotic disease (4). In descending order, the arteries most
affected by atherosclerosis are the abdominal aorta, the coronary arteries, the popliteal
arteries, the descending thoracic aorta, the internal carotid arteries, and the arteries of the
circle of Willis (2). In all of these vessels, there exists a characteristic pattern of
distribution of atherosclerotic plaques, with most lesions located at the ostia of branches
(2, 8).

Atheromas, or atherosclerotic plaques, consist of varying proportions of cells
(e.g., smooth muscle cells, macrophages, and leukocytes), connective tissue extracellular
matrix (e.g., collagen, elastins, and proteoglycans), and lipid deposits (e.g., intracellular
and extracellular cholesterol or cholesterol esters) (1-3). These components collect
within the intima of the arterial wall, leading to intimal thickening followed sequentially
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by development of a fatty streak, atheroma, and fibrous plaque (3, 7). In addition, as they
advance in age and complexity, atheromas develop a fibrous cap composed of cells and
dense connective tissue, all within the intima and covered by the endothelium of the
artery.

This process of atheroma evolution is believed to begin very early in life as fatty
dots, less than 1mm in diameter, which then coalesce to form fatty streaks. These streaks
form the precursors of fully developed atherosclerotic plaques, though the exact
mechanisms are not fully known. Evidence for this relationship comes from autopsy data
which shows that fatty streaks, which are nearly universal in children, occur at the same
anatomic locations that are later prone to have plaques. In addition, as children grow
older and develop more plaques, the number of fatty streaks decreases, suggesting that
they may be evolving into plaques. Risk factors known to be associated with
atherosclerosis are also associated with fatty streaks early in life. It is important to note,
however, that though atherosclerotic plaques may develop from fatty streaks, not all fatty
streaks will develop into plaques or more advanced lesions (2, 9).

As these fatty streaks progress, they become atheromas, with varying amounts of
cells, lipids, and extracellular matrix. This progression is described by the American
Heart Association classification of atherosclerotic lesions (Table 1). As these atheromas
evolve and become more numerous, they can lead to a number of complications.
Possible complications include occlusion of smaller arteries, distal embolization,
hemorrhage into the plaque, and destruction of larger arteries with invasion of the arterial
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media. This latter complication can cause disruption of normal wall mechanical
properties leading to thrombosis, aneurysm, or rupture. Perhaps the most clinically
important complication is focal rupture or ulceration of the plaque with precipitation of
thrombosis of the vessel. A “complicated” atherosclerotic plaque can also possess
variations from the generic structure. These variations include calcification, which can
be used as a marker for advanced disease as described below (2).

Criteria for American Heart Association Lesion Classification System and Correspondence Vlth
Classification of Gross Arterial Specimens*
AHA Grade

Criteria

Comments and Corresponding
Gross Classification

0

Normal artery with or without adaptive
intimal thickening; no hold

Normal tissue

1

Isolated MFCs containing lipid; no extracellular
lipid; variable adaptive intimal thickening
grossly with lipid staining

Initial atherosclerotic lesion, sometimes
visible grossly with lipid staining

2

Numerous MFCs, often in layers, with fine
particles of extracellular lie id; no distinct
pools of extracellular lipid: variable adaptive
intimal thickening

Fatty streak, visible grossly with
III staining

Numerous MFCs with i pools of extracellular
lipid; no well-defined core of
extraceltular lipid

Fatty plaque, raised fatty streak,
intermediate lesion, or transitional lesion

4

Numerous MFCs plus well-defined core of
extracellular lipid, but with luminal
surface covered by relatively normal intima

Atheroma, fibrous plaque, or raised lesion

5

Numerous MFCs, well-defined core or multiple
cores of extracellular lipid, plus
reactive fibrotic cap, vascularization,
or calcium

Fibroartherema, fibrous plaque, or raised
lesion

6

All of the above plus surface defect, hematoma,
hemorrhage, or thrombosis

Complicated lesion

MFC indicates macrophage foam cell; AHA, American Heart Association

Table 1. American Heart Association atherosclerotic lesion classification system.
(Reproduced from Rackley C.E. 2001. Pathogenesis of atherosclerosis. In UpToDate
ed. 9.3, www.uptodate.com)
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The clinical importance of atherosclerosis depends upon the chronic and acute
impedance of blood flow via stenosis of the vessel lumen or via distal embolization. The
original response of the arterial vessel to the atherosclerotic plaque is positive
remodeling, a process which preserves the arterial lumen by outward growth of the
vessel. As the capacity of the vessel to remodel outward is exceeded, the process of
negative remodeling, which encroaches on the vessel lumen, begins to interfere with
normal blood flow (3, 7). Thus, a plaque is quite large before it starts to impinge on the
vessel lumen. Positive and negative remodeling are depicted in Figure 1. Plaque growth
can occur via inclusion of more cells and extracellular matrix as well as by repetitive
cycles of superficial plaque erosion with subsequent thrombosis and healing. The
manifestations of atherosclerotic disease generally affect the coronary, cerebral, lower
extremity and intestinal vasculature. As the plaque grows larger, over the course of many
decades, the plaque may cause decreased blood flow during times of increased demand,
resulting in symptoms such as angina pectoris or claudication. However, in many cases,
acute coronary events such as myocardial infarction occur without prior symptoms, with
the likely mechanism being acute rupture of the fibrous cap or erosion into the plaque
with subsequent thrombus formation occluding the vessel lumen. In these cases, the
disease is often deadly. For example, 1 out of every 3 initial coronary attacks is fatal (34). Distal embolization of plaque or thrombus can also result in clinical symptoms such
as transient ischemic attacks, stroke, or intestinal ischemia.

Figure 1 (on following page). A schematic life history of the atherosclerotic plaque
demonstrating positive and negative remodeling. (Reproduced from Libby P. 2001. The
vascular biology of atherosclerosis. In Heart Disease: A Textbook of Cardiovascular
Medicine. E. Braunwald, D. Zipes, and P. Libby, editors. Philadelphia: W.B. Saunders
Company. 995-1006)
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Molecular and Cellular Biology

The molecular pathology and pathogenesis of these lesions is summarized in the
“response to injury” hypothesis, which states that atherosclerosis is a chronic
inflammatory process within the arterial wall in response to injury to the endothelium (2).
The hypothesis consists of the following steps: focal chronic injury to the endothelium
with resultant endothelial dysfunction, insudation and modification of lipoproteins,
immigration of monocytes and leukocytes with subsequent conversion of monocytes into
macrophages and foam cells, release of molecular factors causing migration of smooth
muscle cells from the media into the intima, proliferation of smooth muscle cells and
elaboration of extracellular matrix, and continued accumulation of lipids both
intracellularly, within macrophages and smooth muscle cells, and extracellularly. These
steps and their molecular and cellular participants are described in detail below and
summarized in Table 2 and Figure 2.
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Event
1. Chronic endothelial
injury causing increased
endothelial permeability
and leukocyte adhesion
2. Lipoprotein insudation
and modification

Mechanism
—Hemodynamic
disturbances
—Hypercholesterolemia
—Oxidative injury

Molecular Players
ICAM-1, VCAM-1,
E-selectin, P-selectin

Oxidized LDL, superoxide,
scavenger receptor

—Monocyte/Macrophage
recruitment
—Foam cell formation

3. Recruitment of
monocytes with formation
of foam cells

4. Immigration and
proliferation of smooth
muscle cells

5. Continued progression

—Direct toxicity
—Chemotaxis and cell
adhesion
—Elaboration of cytokines,
chemokines and growth
factors leading to growth of
lesion and immigration of
smooth muscle cells and
leukocytes
—Continued smooth muscle
cell proliferation
—Elaboration of
extracellular matrix
—Formation of complicated
plaque

IL-1, TNFa, MCP-1

PDGF, FGF, TGFa, TGFp,
collagen, elastin,
proteoglycans

Calcium, bone
morphogenetic protein-2a,
osteopontin, osteonectin,
—Calcification
osteocalcin, matrix
metalloproteinases, Gla—Rupture
proteins, IL-6, estradiol
Table 2. A summary of the steps in the “response to injury” hypothesis and some of the
key molecular mediators. (Abbreviations: ICAM-l=intercellular adhesion molecule-1,
VCAM-l=vascular cell adhesion molecule-1, E-selectin=endothelial selectin, Pselectin=platelet selectin, LDL=low density lipoprotein, IL=interleukin, TNFa=tumor
necrosis factor-a, MCP-l=monocyte chemoattractant protein-1, PDGF=platelet derived
growth factor, FGF=fibroblast growth factor, TGF=transforming growth factor, Glaprotein=gamma carboxyglutamate containing protein)
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Advemrtra
Chronic
endothelial
■injury":
• Hyperlipidemia
• Hypertension
- Smoking
• Homocysteine
• Hemodynamic factors
• T oxins
• Viruses
• Immune reactions,

Endothelial dysfunction
(e g , increased permeability
leukocyte adhesion)
Monocyte adhesion
and emigration.

3. Smooth muscle
emigration from media
to intima. Macrophage
activation..

4. Macrophages and \
smooth muscle cells
engulf iipid

I

Response to injury

I
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Figure 2 (on preceding page). Schematic showing steps in the “response to injury”
hypothesis. (Reproduced from Schoen F.J., and Cotran R.S. 1999. Blood vessels. In
Robbins Pathologic Basis of Disease. R. Cotran, V. Kumar, and T. Collins, editors.
Philadelphia: W.B. Saunders Company. 493-541)

The process of atherosclerosis in this model begins with endothelial dysfunction
resulting from chronic injury to focal areas of endothelium. The dysfunction is manifest
in increased endothelial permeability and enhanced leukocyte adhesion through
endothelial cell expression of intercellular adhesion molecules of the immunoglobulin
superfamily (e.g., intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1)) and the selectins (e.g., endothelial selectin (E-selectin) and
platelet selectin (P-selectin)) (2-3). This dysfunction is distinct from normal arterial
endothelium, which is resistant to adhesive interactions with circulating cells, and from
inflamed tissue, in which the process of inflammatory cell recruitment occurs in the post¬
capillary venule, not the artery or arteriole (3). Many initiating factors for endothelial
injury have been suggested, including endotoxins and infectious agents, hypoxia,
products contained in cigarette smoke, and endothelial toxins such as homocysteine (2,
7), but the concept of endothelial injury in this hypothesis relies on two main mechanisms
of injury. One stems from hemodynamic disturbances while the other stems from the
adverse effects of hypercholesterolemia. The finding that most atherosclerotic plaques in
large arteries occur in the area of ostia to branch arteries is well defined and lends support
to the first mechanism (2, 8). In addition, it is known that disturbed flow induces
proatherogenic activities in the endothelium, including the adhesion molecules mentioned
above, while smooth laminar flow actually induces antiatherogenic, or atheroprotective,
gene products such as the antioxidant superoxide dismutase (2-3).
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Hyperlipidemia, specifically hypercholesterolemia, also contributes to
atherogenesis. The mechanisms underlying this activity include production of oxygen
free radicals leading to endothelial injury and insudation of lipoproteins within the intima
at sites of increased endothelial permeability, thus beginning the formation of the fatty
streak. This leads to the modification of these lipoproteins via oxidation by oxygen free
radicals (2-3). These modified lipoproteins are then ingested via the scavenger receptor
of macrophages which, unlike the normal LDL receptor, is able to ingest modified LDL
(3). This process leads to foam cell formation, chemotaxis of circulating monocytes,
monocyte adhesion, recruitment and retention within the lesion, release of cytokines and
growth factors, and direct injury to endothelial and smooth muscle cells (2). It is at this
level that the beneficial effects of antioxidants such as vitamin E and betacarotene may be
manifest (7).

In conjunction with the role of lipoproteins, circulating monocytes are recruited to
the area of the lesion via the expression of the specific adhesion molecules discussed
above. The selectins contribute to the saltatory motion of circulating cells while the
immunoglobulin family molecules contribute to binding of the cells to the endothelium.
Chemotaxis due to oxidized LDL and the resultant expressed cytokines then leads to the
diapedesis of these cells into the intima, the ingestion of oxidized LDL via the scavenger
receptor, and the formation of foam cells (2-3). These cells now play a significant role in
the progression of the plaque. They release the important cytokines interleukin-1 (IL-1)
and tumor necrosis factor-alpha (TNF-a), and the chemokine monocyte chemoattractant
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protein-1 (MCP-1), all of which further the recruitment of monocytes and leukocytes. In
addition, they elaborate chemokines and growth factors which lead to the migration of
smooth muscle cells from the media into the intima and their subsequent proliferation (23). With the continuation of these processes through continued endothelial injury and
persistent hypercholesterolemia, these lesions grow and aggregate, forming fatty streaks.
If the hypercholesterolemia is treated, the lesions up to this point may regress without
progression (2-3).

The next steps in the progression of the atherosclerotic lesion are important to the
conversion from fatty streak to mature atheroma and subsequent complicated plaque (2).
As smooth muscle cells, normally quiescent cells within the media of the arterial wall,
migrate into the intima and proliferate, they synthesize an extracellular matrix composed
of collagen, elastin, and glycoproteins (2-3). This process is governed by the cytokines
and growth factors elaborated by the adherent platelets and leukocytes, macrophages and
foam cells, endothelial cells, and the smooth muscle cells themselves. These factors
include platelet derived growth factor (PDGF), fibroblast growth factor (FGF), and
transforming growth factor-alpha (TGF-a) and beta (TGF-(3) (2-3).

Progression of the plaques from these early lesions involves maturation of the
core from a simple aggregation of foam cells derived from macrophages and smooth
muscle cells to a cellular-fatty atheroma consisting of surviving foam cells, dead cells
with cellular debris and extracellular lipids, and deposited collagen and proteoglycans. In
addition, the connective tissue on the intimal aspect is organized into a fibrous cap. As
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they age, these fibrofatty atheromas can undergo further connective tissue proliferation to
become fibrous plaques. The larger plaques, like neoplasms, also stimulate adjacent
angiogenesis through mediators such as vascular endothelial growth factor (VEGF) (3).
In addition, these lesions can progress to “complicated” plaques as described in the
section on pathogenesis. For example, the important event of rupture and thrombus
formation is thought to originate with the digestion of the extracellular matrix and fibrous
cap by matrix metalloproteinases released by resident macrophages (1,3, 9).

Another feature, calcification of the plaque, is of particular interest to this study
and is therefore described here in some detail. One of the modifications which defines a
plaque as “complicated” is mineralization with calcium. The process is likely a dynamic
interaction of cells and mediators with regulation similar to the process of bone formation
(3, 9, 10). Important mediators of this regulation are intercellular messenger molecules,
such as interleukin-6 (IL-6) and estradiol (11). In addition, the plaques contain bone
morphogenetic protein-2a, a potent factor influencing osteoblast differentiation, and often
contain fully formed bone tissue, including marrow (9, 12). Other factors involved in the
process are osteopontin, osteonectin, and osteocalcin, all known to be involved in bone
mineralization, and proteins containing gamma carboxyglutamate (Gla), a rare amino
acid whose only known function is to bind calcium (9). Also, cells that are known to be
capable of osteoblastic differentiation and which may be the predecessors of vascular
calcifying cells are found in atherosclerotic plaques (9). Though calcification does define
a plaque as being advanced and complicated, the presence of calcification in itself does
not predispose to complications of atherosclerosis. In fact, some studies suggest that
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calcification of the arteries due to atherosclerosis, though a useful marker of
atherosclerosis (see below), may actually strengthen a plaque, thus preventing it from
undergoing complications leading to clinical events (9 13, 14).

Epidemiology

The social importance of arteriosclerosis is well known, and can be defined by
examining the epidemiological and health-care cost data available. All atherosclerotic
cardiovascular disease was estimated to account for $259 billion dollars of health care
costs in 1997, up from $210 billion dollars in 1993. The biggest portion of this amount
consisted of $51 billion dollars for coronary heart disease alone, followed by $35.5
billion dollars for congestive heart failure and $19 billion dollars for stroke (4). In 2002,
the estimated direct costs of major atherosclerotic disease, consisting of coronary heart
disease, stroke, and congestive heart failure, are $110.4 billion dollars. This estimate
does not include the indirect costs of these diseases from lost productivity and does not
include other atherosclerotic diseases such as lower extremity gangrene (15).

The clinical importance of arteriosclerosis is evident when examining the
epidemiological data on the prevalence and associated mortality and morbidity of
atherosclerosis. Although atherosclerosis is a diffuse process capable of involving any
vascular territory in the body, symptomatic atherosclerotic disease most often involves
the heart, brain, kidneys, lower extremities and intestines. For this reason, data about
incidence and prevalence of atherosclerotic disease are generally expressed in reference
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to ischemic coronary heart disease (CHD) and its consequences (e.g., angina, myocardial
infarction, congestive heart failure), cerebrovascular accidents (CVA), end organ
infarction and ischemia, and gangrene of the limbs (2). Atherosclerotic disease and its
clinical consequences account for over half of all deaths in the developed world (2), and
have been the number one killer in the United States since 1900 (15). Fatty streaks are
nearly ubiquitous, with one study demonstrating that all teenagers in the United States
who were sampled had fatty streaks somewhere in their arterial system (16). The
prevalence of more advanced atherosclerosis increases as the patient ages, with
atherosclerotic plaque present in 50% of individuals aged 20-29 years but in 80% of
individuals aged 30-39 (9). Although on the decline in recent years due to prevention and
advances in medical care, coronary heart disease (CHD) independently remains the
leading cause of death in the United States (2, 17-19). Approximately 12 million people
in the United States have CHD (Figure 3), resulting in over 500,000 deaths per year (4,
15, 18,20).

Figure 3 (on following page). Prevalence of coronary heart disease by age and sex
(United States: 1988-1994). (Adapted from American Heart Association. 2001. 2002
Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association)
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□ Men
□ Women

Some data do exist for the presence of atherosclerotic calcification in the
population. Calcification of the vasculature is present in 50% of individuals aged 40 to
49 years, and 80% of individuals aged 60 to 69 (9). In one study, calcified plaques
specifically in the thoracic aorta were present in 8.5% of men and 3.9% of women aged
40 to 44 years, with equalization of the sexes by age 60 and more than 80% in both sexes
at age 75 to 80 (6,21-22).

Risk Factors

Several large prospective clinical trials have identified many risk factors, both
constitutional and acquired, which contribute to the pathogenesis and evolution of
atherosclerosis. The major risk factors are described in more detail below and are shown
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in Table 3 along with some minor and uncertain risk factors. Age, sex, family history
and genetics are the constitutional factors (2, 9, 15).

Major
Constitutional
Increasing age
Male gender
Genetics
Potentially Controllable
Hyperlipidemia
Hypertension
Cigarette smoking
Diabetes mellitus

Lesser, Uncertain, or Nonquantitated
Obesity
Physical inactivity
Stress
Homocysteine
Postmenopausal estrogen deficiency
High carbohydrate intake
Alcohol
Lipoprotein (a)
Hardened (trans) unsaturated fats
Chlamydia pneumoniae

Herpes viruses
Table 3. Risk factors for atherosclersosis. (Adapted from Schoen F.J., and Cotran R.S.
1999. Blood vessels. In Robbins Pathologic Basis of Disease. R. Cotran, V. Kumar, and
T. Collins, editors. Philadelphia: W.B. Saunders Company. 493-541)

Probability (%)
Age (y)
Women
Men
30-34
<1
3
35-39
<1
5
40-44
2
6
45-49
5
10
50-54
8
14
55-59
12
16
60-64
13
21
65-69
9
30
70-74
12
24
Table 4. Average 10-year risk of coronary leart disease based on age and gender.
(Adapted from Kannel, W.B. 1998. Overview of atherosclerosis. Clinical Therapeutics.
20, Supplement B: B2-B17)
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As is evident from the description of pathogenesis and molecular biology,
atherosclerosis begins early in life and becomes progressively worse over the course of
the lifespan to the point of becoming clinically relevant after middle age.

One possible

mechanism of this correlation may be a decrease in elasticity as the artery ages (8). The
prevalence of CHD is age-dependent (Table 4), with an increase from 86 per 1000 men at
ages 45 to 64 up to 169 per 1000 men at ages 65 and older suffering from CHD. These
numbers in women, though slightly lower, are substantial and on the rise (4). In addition,
1 in every 3 males and 1 in every 10 females in the United States suffers a major
atherosclerotic cardiovascular event before the age of 60 years. This risk for these events
is also age-dependent, with the annual rate increasing from 5 per 1000 in the 35 to 44 age
range to 59 per 1000 in the 85 to 94 age range (4). An additional example is the five-fold
increase in the incidence of myocardial infarction from age 40 to age 60 (2). Some of
these data are presented in a different form in Figure 4.

Additional data show that the male sex is also an independent factor in the
prevalence of atherosclerosis (see again. Table 4), though the distinction between sexes
becomes insignificant after the age of menopause as the occurrence of atherosclerotic
events accelerates in women (Figure 4). There is some data supporting the idea that this
trend is due to a favorable lipid profile and better endothelial function associated with
higher levels of estrogen (2, 9).

Figure 4 (on following page). The incidence major cardiovascular events in 36-year
follow-up of the Framingham Study (Reproduced from Kannel, W.B. 1998. Overview
of atherosclerosis. Clinical Therapeutics. 20, Supplement B: B2-B17)

22

Age:

Risk Ratio:
65-94/35-64

35-64
65-94
Peripheral
Arterial Disease
(1C)
Men
Women
1.5
3.0

35-64
65-94
Congestive
Heart
Failure
Men
Women
3.7
4.5

35-64
65-94
Stroke
and TIA
Men
4.0

Women
5.5

35-64
65-94
Coronary
Heart
Disease
Men Women
1.9
2.8

The final constitutional factor is genetics. Familial clustering of atherosclerosis
certainly exists. The process is likely polygenic, and often linked to other risk factors
such as diabetes or hypertension. There also exist well-defined familial diseases of lipid
metabolism leading to hyperlipidemia with and without hypercholesterolemia (2).

Many of the major risk factors for atherosclerotic disease are acquired or
controllable with therapy or lifestyle modification. These include hyperlipidemia,
hypertension, smoking, and diabetes (2, 4, 15, 23-24). It is at the level of these factors
that the greatest strides have been made in reducing the incidence of atherosclerosis
related disease over the past several decades with the use of primary and secondary
prevention (2, 15).
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Hyperlipidemia is an obvious offender when one analyzes the molecular biology
of atherosclerosis as described above. The proof for the relationship lies in the high
incidence of atherosclerotic disease present in high lipid states such as familial
hypercholesterolemia and diabetes. In addition, it has been proven that the higher the
level of cholesterol, the greater the severity of atherosclerosis, with an exponential
increase after exceeding 200mg/dl of total cholesterol. Many studies have also shown
that a decrease in serum cholesterol with diet and lipid-lowering drugs leads to a decrease
in atherosclerotic disease (2, 9).

Hypertension is also a controllable risk factor, and is actually a stronger risk
factor for atherosclerosis than hypercholesterolemia after age 45 years. Both systolic and
diastolic pressures are important, and control of blood pressure with antihypertensive
therapy reduces the incidence of atherosclerotic disease (2).

Cigarette smoking is a well-established risk factor for both men and women, and
is believed to have contributed to a recent increase in the incidence of atherosclerosis in
women (2, 9). As with aging, smoking has been shown to decrease the elasticity of
arteries, thereby leading to flow changes which may lead to hemodynamic endothelial
injury (8). Smoking can cause a 200% increase in the death rate from ischemic heart
disease when one or more packs are smoked per day for several years. This risk is
partially reversible, as cessation of smoking halves this increase in risk (2).

The last major risk factor is diabetes mellitus. Diabetes can induce
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hypercholesterolemia and has been shown to nearly double the risk of myocardial
infarction as compared to nondiabetics. The most prevalent atherosclerotic disease in
diabetics is atherosclerosis-induced gangrene of the lower extremities, the risk of which
is increased by a factor of 100 in diabetics versus nondiabetics (2).

Many other minor and uncertain risk factors exist, as described in Table 3. One
important facet of this data is that atherosclerosis can develop in the absence of any
known or hypothesized risk factor, emphasizing the fact that this field is still actively
evolving and its true pathogenesis remain highly speculative (2). Another important fact,
summarized in Figure 5, is that the risk factors are not merely additive when
compounded. They are somehow synergistic so that two risk factors increase the risk of
atherosclerotic disease fourfold, while three risk factors increase the risk sevenfold (2).
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Figure 5 (on preceding page). Estimated 10-year risk of coronary heart disease
according to various combinations of risk factor levels. (Reproduced from Schoen F.J.,
and Cotran R.S. 1999. Bloodvessels. In Robbins Pathologic Basis of Disease. R.
Cotran, V. Kumar, and T. Collins, editors. Philadelphia: W.B. Saunders Company. 493541)

Imaging

Imaging of atherosclerosis in vivo is an important method of identifying and
following patients with atherosclerotic disease. Imaging of the coronary arteries by
noninvasive means is difficult but possible with certain modalities. Another potential
target for imaging is the aorta. Many studies demonstrate that atherosclerosis of the aorta
correlates well, positively and negatively, with the presence of the generalized
atherosclerotic process (1, 5, 9, 25). This relationship seems especially useful for
younger patients (6, 26).

Imaging of atherosclerosis can be accomplished by a variety of modalities. The
list of modalities continues to grow with the advent of newer technologies and imaging
techniques such as electron-beam computed tomography (EBCT) and “black-blood”
magnetic resonance imaging (MRI) (1, 13, 27-28). The primary modalities are
echocardiography, fluoroscopy, and computed tomography. These modalities, as they
pertain to this study, will be discussed below.

Echocardiography, specifically transesophageal echocardiography (TEE), is a
noninvasive modality ideal for the detection, measurement and characterization of
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atherosclerotic plaques of the aorta. It is able to detect intimal thickening, often the first
detectable sign of atherosclerosis, ulceration, and calcification, and has the ability to
grade plaques based on these characteristics (13, 26, 29). There are limitations of TEE,
however, for the puiposes of this study. For example, TEE cannot fully visualize the
ascending aorta and arch due to its anatomic relationship to the trachea (13, 30). TEE can
also visualize only the proximal coronary circulation with a good degree of resolution,
and does not provide adequate imaging for the detection of coronary calcium. In
addition, without advance specification requesting characterization of the aorta, most
echocardiographers do not focus on obtaining adequate images of the descending aorta.
Although a versatile tool in the detection of atherosclerosis of the aorta, TEE was not
considered a useful imaging modality in this retrospective study due to these limitations.

Fluoroscopy is an excellent imaging modality for the detection of significant
atherosclerotic disease by its virtue of being able to detect lesions which impinge on the
lumens of the coronary arteries or the aorta. This modality is also useful in detecting
moderate to large levels of coronary and aortic calcification, though its sensitivity for
lesser amounts of calcium is limited (9). In addition, coronary angiography and
aortography are invasive procedures which not all patients qualify for due to risks
inherent in the procedure and the use of fluoroscopic dye. For the purposes of this study,
not all patients in the Marfan group received coronary angiography or aortography. In
addition, no valid control group of patients exists which adequately represents the general
population.
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Conventional computed tomography (CT) is extremely useful for the specific
purpose of detecting vascular calcification (9). The specificity of coronary calcification
seen on CT for significant coronary artery disease are 78% to 100% in studies comparing
CT to angiographically significant stenosis, with a positive predictive value of 83% to
100%, suggesting that if coronary calcium was seen on CT, significant coronary artery
disease was likely to be present (9). In addition, computed tomography is also useful in
assessing the entire thoracic aorta, allowing for even better sensitivity and specificity for
significant atherosclerotic disease (9, 13). Some studies suggest that the presence of
atherosclerotic lesions in the thoracic aorta possesses both a strong positive predictive
value and a high negative predictive value (as high as 79% in one study) for coronary
artery disease, suggesting that noninvasive detection of aortic atherosclerosis is a useful
and reliable marker for significant atherosclerotic disease in the patient (5, 25). Electron
beam CT, a novel technique which allows for very exact quantification of coronary
calcium, is extremely useful for assessing the degree of atherosclerotic disease (1,9, 13).
This new technique, however, is not universally available and is too recent to be available
for this retrospective study. Conventional CT, however, is universal and has been used in
assessing the severity of atherosclerotic disease by use of a semi-quantitative calcification
grading scale which correlates well with the exact quantification of electron beam CT (1,
10, 22, 30-32). This can be accomplished within the coronary arteries, and more so
within the aorta, the larger size of which makes it an easier subject of imaging. CT is
also useful for the purposes of this study because many Marfan patients are followed with
serial CT scans for assessment of aortic aneurysm growth (see details of Marfan and
quantitative method below).
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Calcification of vessels has been shown to be a definite marker of atherosclerotic
disease. Detection of atherosclerosis of the coronary arteries and aorta via identification
of calcification within these arteries is a reliable indicator of presence and severity of
atherosclerotic disease (9, 14). For example, calcification of the coronary arteries occurs
exclusively in atherosclerotic arteries, sparing normal vessels (9). Thus, calcification of
the aorta and coronary arteries, visualized with CT, is a marker for atherosclerosis of
these vessels. In addition, atherosclerosis of the aorta itself is a significant marker for
coronary artery disease (1, 27, 33-37). To extend this relation farther, since
atherosclerosis is a diffuse process, the calcification of these vessels is also an indicator
of generalized atherosclerotic disease (1,9). Since the aorta and coronary arteries are
among the most frequently affected vessels, as described above, their use as markers for
atherosclerotic disease is also extremely sensitive. In addition, this relationship is most
significant when studying patients younger than 65 years of age (6, 26, 34). Calcification
of the coronary arteries and aorta is thus ideal for the study of the relatively young
Marfan patient population in this study.

Background on the Marfan Syndrome

Definition

First described in 1896 by the Parisian pediatrician Auguste Marfan, the Marfan
syndrome has become a prototypical example of the group of syndromes collectively

29

known as the disorders of connective tissue. Marfan syndrome (MFS), with an incidence
of approximately 1 in 10,000 to 20,000 live births and a prevalence of 1 in 3,000 to 5,000
individuals, is an autosomal dominant condition caused by mutations in the FBN1 gene
encoding the extracellular molecule fibrillin-1 (38-43). The lifespan of patients with
MFS has increased steadily over the past decades as treatment modalities evolve. In
1972, the average lifespan for a patient with MFS was 32 years. This number increased
to 41 years in 1993 and 61 years in 1996, and now approaches the normal lifespan of the
population.

For as yet unknown reasons, the lifespan of patients with MFS is

significantly lower in men than in women (38, 41, 43-44).

Features and Diagnosis

MFS lies at the extreme end of a spectrum of disease conditions, the
fibrillinopathies, ranging from variations of normal to individual features of MFS to MFS
(41, 44). MFS is a pleiotropic disease involving abnormalities in multiple organ systems,
most notably the ocular, musculoskeletal, and cardiovascular systems (38, 39, 41, 44).
The diagnostic criteria for MFS were recently updated by the group from Gent, Belgium
(39), and are listed in Table 5, while the differential diagnoses of MFS are listed in Table
6. The classic, diagnostic features of MFS and some of their treatments are described
here, with particular emphasis on the cardiovascular manifestations of the disease. In this
revised scheme, “major” criteria are those which carry high specificity for MFS due to
relatively low frequency in other conditions and the general population (39).
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Ocular manifestations of MFS include ectopia lentis, with upward dislocation of
the lens unilaterally or bilaterally, myopia secondary to the increased length of the globe
and flattening of the cornea, retinal tears and detachment, and glaucoma (38-39, 41-42).
Dislocation of the lens, one of the most recognized ocular abnormalities of MFS, occurs
in approximately 60% of patients with the disease. Conservative correction of vision
with ectopia lentis in MFS is usually attempted prior to surgical correction with lens
removal and replacement. Though a major diagnostic manifestation of MFS, ectopia
lentis does occur as an isolated disease in some patients with FBN1 mutations who do not
meet diagnostic criteria for MFS (38, 41). This underscores the importance of the Gent
criteria and will be discussed in more detail in the section on molecular biology and
genetics.

Ma|or criteria
family history

Ocular

f urst-degree relative who meets diagnostic criteria
.Warfan-caosing FBN 1 mutation
Haplofype around F&F4! associated with
confirmed Marfan inherited by descent
Presence erf any four of the following:
Pectus carirtatum
Pectus excavratwo requiring surgery
Reduced upper segment-lower segntertt ratio
0# sparulseight >1.05
Positive wrist and thumb signs
Scoliosis >20 degrees or spondyloWshesis
Extension <170 degrees at elbow
Medial displacement of the medial malleolus
causing pes planus
Protrusio acmbulae
Ectcpla lentis

Cardiovascular

Dilation of die ascending aorta with or with¬

Skeletal

out aortic regurgitation involving at least the
sinuses ui Valsalva
Dissection of the ascending aorta

Pulmonary

Koto

SWn and central
nervous system

Lumbosacral dural ectasia

Minor criteria

Involvement

None

Major Criterion must be met
or family history is
TOTOontributoiy

Pectus excavatum
Joint hypermobility
High arched palate with dental
crowding
facial appearance

1 wo of the components of the
major criteria or me of the
components of the major
criteria and two minor criteria

fiat cornea dry ketatometryi
increased globe length (by ultrasounds
Hypoplastic iris or hypoplastic ciliary
muscle causing decreased miosis
Mitral valve prolapse with or without
mitral regurgitation
Dilation of main pulmonary artery
without other cause at age 40 years
or younger
Calcification of the mitral annulus at
age 40 years or younger
Dilation or dissection of she descend¬
ing thoracic or abdominal aorta at
age 50 years or younger
Spontaneous pneumothorax
Apical Webs {radiographically)
Striae atrophicae not associated with
marked weight changes, pregnancy;
or repetitive stress
Recurrent or incisional hernia©

Two minor Criteria

*To make a d&tgnas-lt of Marfan syndrome in an sffcfcvkftual
no family hlssory requires major* crisers in two organ systems
a family history, major criteria must be met >n one organ system and another musl be Involved.

One major or one minor
criterion

One minor criterion
One major or one minor
criterion

Involvemerw of a ?hird. \i there it
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Table 5 (on preceding page). Diagnostic criteria for the Marfan syndrome according to
the revised 1996 Gent criteria. (Reproduced from Wright M.J., and Dietz, H.C. 1999.
Heritable disorders of connective tissue. In Oski’s Pediatrics: Principles and Practice.
J.A. Mcmillan, C.D. DeAngelis, R.D. Feigin, and J.B. Warshaw, editors. Philadelphia:
Lippincott Williams & Wilkins. 1892-1899)

Common Skeletal Manifestations
Classic Ehlers-Danlos syndrome (MTM 130000, 130010, 130020)
Sickle-cell disease (M1M 141900.0243)
Multiple endocrine neoplasia type III (MIM 162300)
Trisomy 8
Kline fe 1 ter s y n drome
Congenital contraetural arachnodactylv (MIM 121050)

Common Ocular Findings
Ehlers-Danlos syndrome, kyphoscoliosis form (type VI; MIM 225400)—retinal detachment
Wcill-Marchcsani syndrome (MIM 277600)—ectopia Icntis
Autosomal dominant ectopia lends (MIM 129600)
Autosomal recessive ectopia lends with (MIM 225200) and without (MIM 225100) ectopic
pupils

Common Cardiovascular Features
Mitral valve prolapse
MASS phenotype (familial mitral valve prolapse; MIM 157700).
Dilatation of the ascending aorta
Tertiary syphilis
Ankylosingspondy litis
Rel apsing polychondriti s
Reiter syndrome
Familial aortic aneurysm (MIM 132900)
Bicuspid aortic valve, coarctation of the aorta, and medial degeneration of the ascending aorta

Table 6. The differential diagnosis of Marfan syndrome. (Reproduced from Pyeritz R.E.
2000. The Marfan syndrome. Annual Review of Medicine. 51:481-510)
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The main musculoskeletal features of MFS are arachnodactyly, confirmed by the
thumb and wrist signs, tall stature with decreased upper body to lower body ratio and arm
span exceeding height, generalized joint hypermobility, protrusio acetabuli, and disorders
of tubular bone overgrowth, manifest as scoliosis and pectus deformities (38-39, 41-42,
44). Since many of these musculoskeletal features are common in the population, a
combination of multiple defects is required for involvement of this system (39). A
positive thumb sign for arachnodactyly means that the distal phalanx or entire fingernail
of the thumb protrudes beyond the fifth digit when the fist is clenched. A positive wrist
sign means that the thumb and fifth digit overlap when circling the contralateral wrist.
Scoliosis and pectus deformities may require surgical correction if the subsequent
restrictive pulmonary disease and cor pulmonale is morbid, but these corrections must be
timed to avoid recurrence due to continued bone growth (41-42).

The main cardiovascular features of MFS are aneurysmal aortic dilatation, with
and without aortic regurgitation, aortic dissection and/or rupture, and mitral valve
prolapse (38-39, 41, 44). Prior to the development of successful surgical intervention,
these cardiovascular features accounted for over 90% of mortality in MFS (41-42).
Dilatation of the aorta is found in 50% of children with MFS, and progresses with time to
involve 60% to 80% of adults. Many patients have involvement of other segments of the
aorta (38, 43). In addition, other arteries, including the pulmonary artery, the carotids,
and cerebral vessels may display dilatation (38). Aortic dissections occur more
frequently as the aorta becomes progressively more dilated, with the majority being Type
A dissections originating at the aortic root (38, 44).
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Mitral valve prolapse is also common in MFS, but due to its high prevalence as an
isolated entity, it is only a minor criterion for MFS. In MFS, mitral valve prolapse occurs
with higher incidence in women and with age (38). The cause of mitral valve prolapse in
MFS, as with isolated mitral valve prolapse, seems to be a redundancy of the valve
leaflets with dilatation of the mitral annulus and stretching of the chordae tendinae. In
addition, the annulus in these patients is often calcified (38, 41); this fact is particularly
relevant to the present study in demonstrating that patients with MFS do seem to have
normal, active calcification of damaged endothelial and vascular structures.

The management of aortic disease in patients with MFS has progressed
dramatically in the past few decades with the development of composite graft
replacement surgery of the aortic valve and ascending aorta and the demonstration of a
potential prophylactic benefit with the use of beta-blockers and possibly calcium channel
antagonists. (38, 41, 43-44). Elective repair of the aortic root, when the root diameter
exceeds twice the upper limit of normal for an individual’s body surface area, is optimal
(38, 41-42). The 30-day mortality for elective repair is significantly lower as compared
to the urgent (within 1 week of surgical consultation) and emergent repairs (within 24
hours of surgical consultation) which occur as a result of dissection or impending
dissection (38, 41, 45). In addition, the likelihood of requiring additional aortic surgery
at other sites in the aorta is increased in patients who have a dissection at the time of their
first surgery (38, 45). These statistics are especially important for the management of
pregnant MFS patients, who are at increased risk for acute enlargement of the aortic root
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diameter and dissection (38, 44). Also, as treatment for the cardiovascular manifestations
of MFS are improving, the resultant increase in lifespan has important implications for
the more prominent role of manifestations in the other organ systems involved. In the
case of mitral valve prolapse, mitral valve repair or replacement is often required if heart
failure occurs (41). Another important point in the management of the cardiovascular
features of MFS is antibiotic prophylaxis during procedures which may introduce
bacteria into the bloodstream, as these patients are particularly prone to bacterial
endocarditis (41).

Other features of MFS include dural ectasia, cutaneous striae densae, and apical
pulmonary blebs with spontaneous pneumothorax (39). The dural ectasia, resulting in
enlargement of the lumbosacral spinal canal with erosion of vertebral bone and potential
meningoceles, occurs in up to 90% of MFS patients but has an uncertain clinical
significance beyond minor nerve compression symptoms (38-39). The cutaneous striae
occur in flexural areas and can often be associated with incisional and inguinal hernias
(38-39).

Table 5 details which of these features qualify as minor and major diagnostic
criteria for NTFS, as well as the requirements for involvement of an organ system. To
achieve an independent diagnosis of Marfan Syndrome by these 1996 Gent criteria (39), a
patient must have major manifestations in two systems with involvement of a third
system. To qualify for a major criterion in the family history or genetic history category,
a patient must have a parent, sibling, or child meeting the independent criteria, or they

35
must possess a mutation in FBN1 known to cause MFS, or they must possess a linked
haplotype around the FBN1 gene which is known to be associated with independently
diagnosed MFS in the family. If a patient has one of these major criteria in the family
history category, then he or she may be diagnosed with MFS if they have a major
manifestation in one system with involvement of a second system. The simple presence
of a mutation in the FBN1 gene is not sufficient for diagnosis due to the wide variation in
phenotype from such mutations. This will be discussed in greater detail below.

Molecular Biology and Genetics

The FBN1 gene, now linked to MFS and other similar disease processes, produces
fibrillin-1, a glycoprotein component of the connective tissue lOnm elastin-associated
microfibril (44). Another fibrillin gene, FBN2, and its product fibrillin-2, have also been
identified and linked to congenital contractural arachnodactyly, but not to MFS (41).
FBN1 is a large gene with 65 exons located at chromosome 15q21.1. Fibrillin-1 and the
connective tissue microfibril are components of both elastic and nonelastic connective
tissues and are essential to normal elastic fibnllogenesis. With many cysteine-rich
sequences, fibrillin-1 is homologous to epidermal growth factor or transforming growth
factor-beta binding protein-1 (38, 46).

There is extensive intragenic heterogeneity, with over 100 mutations in
FBN1 identified in patients with MFS. In addition, many other mutations have been
identified in patients with milder phenotypes that overlap with MFS. Also, at least 25%
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of patients with MFS represent new mutations not present in the family genetic history
(38, 41). These facts make molecular diagnosis of MFS extremely difficult, so that the
clinical diagnostic criteria mentioned above are more precise and still necessary despite
knowledge of the molecular biology of the disease (41-42, 44, 47). In mutations known
to cause MFS, penetrance approaches 100% but wide clinical variation (39, 41, 43-44,
47). Though no exact genotype to phenotype correlations have been defined within MFS,
it seems that patients with exon skipping or in-frame mutations have a more severe
phenotype than do patients with termination mutations (38, 41, 44). This fact is
consistent with the thought that the MFS phenotype is the result of a dominant negative
action of the mutant fibrillin-1 protein (41).

The connective tissue microfibrils are ubiquitous, and act as principal
components of elastic fibers, anchoring fibers between the dermis and epidermis, and as
the ocular zonules (41,47). In the arterial wall, the changes are mainly in the media. The
media of the elastic arteries in patients with MFS display fragmentation and disarray of
the elastic fibers, a decreased amount of smooth muscle cells, and the separation of
muscle fibers by collagen and mucopolysaccharide (41-42). The result of these defects
is increased stiffness and decreased distensibility in the ascending aorta (38, 41, 43).

Arteriosclerosis in the Marfan Syndrome

Very little literature exists regarding the prevalence of arteriosclerosis in patients
with MFS. An extensive literature search using the Medline database revealed no journal
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entries focusing on both Marfan syndrome and arteriosclerosis. One study does find that
the rate of coronary artery disease detected by coronary angiography was significantly
less in patients with acute aortic dissection than in patients with abdominal aortic
aneurysms or arteriosclerosis obliterans, with a rate of 19.7%, 43.9%, and 51.5%,
respectively (48). This study, however, specifically excluded patients with the Marfan
syndrome, thus making difficult any extrapolation to this particular subset of patients
with acute aortic dissections. The experience of the cardiothoracic surgery group at Yale,
however, suggests that patients with MFS do have significantly less arteriosclerotic
disease in their large arteries than do other patients.

Many mechanisms could provide a reason for this observation. The reason could
be a simple age bias, since the operative MFS population tends to be younger than other
cardiothoracic surgery patients. There could be reasons why disruption of the normal
arterial media could provide protection from intimal injury or progression of intimal
lesions. As mentioned above, the defective fibrillin-1 protein is an integral component of
the lOnm connective tissue microfibril. This microfibril interacts with many different
constituents of the extracellular matrix and a defect in the fibril could create difficulties in
the normal inflammatory processes required for arteriosclerosis. For example, loss of the
normal elastic properties of the artery could prevent normal hemodynamic stresses which
cause endothelial injury. This would seem paradoxical, however, due to the increase in
atherosclerosis which occurs with age due, theoretically, to the decreased elasticity of
older vessels. Also, there could be as yet unknown functions of the microfibril, perhaps
in interactions with the thrombotic mechanism or serum lipoproteins, which could link a
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defect in this microfibril to the process of arteriosclerosis. Alternatively, as mentioned
above, there is a decrease in the number of smooth muscle cells in the arterial media of
patients with MFS. Without these smooth muscle cells, normal progression of the
atherosclerotic plaque could not occur. They could not migrate to the intima (due to
decreased number as well as potentially defective migratory properties in the setting of
defective microfibrils) and elaborate the extracellular matrix and intercellular mediators
which build upon the early lesion.

The dearth of knowledge in this area creates an opportunity for ground level
research. It is the aim of this study to probe the relationship between Marfan syndrome
and arteriosclerosis. The specific hypothesis and aims of the study are given below.
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Statement of Purpose

No organized and decisive studies evaluating the relationship between the Marfan
syndrome and arteriosclerosis exist in the medical literature. Nevertheless, the Marfan
syndrome is a disease of the connective tissue of the vessel wall, placing it in a unique
position to interact extensively and by a variety of means with the processes of
arteriosclerosis. It is the observational experience of the faculty of the section of
cardiothoracic surgery at Yale University School of Medicine that patients with Marfan
syndrome who have been operated upon at Yale-New Haven Hospital have had relatively
low rates of overt arteriosclerosis.

This pilot study has been designed to probe the nature of the relationship between
these two important diseases in order to 1) determine the prevalence of arteriosclerosis in
the Marfan syndrome, 2) compare patients with the Marfan syndrome to the general
population in this regard, and 3) begin to understand any lessons each disease may offer
about the other. In time, this work will be developed into a national study with a large
cohort of patients. The hypothesis of this study is that patients with the Marfan syndrome
have significantly less arteriosclerotic disease, as detected by calcification in the thoracic
aorta and coronary arteries on a chest CT scan, than individuals in the general population.
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Methods

Institutional Review Board Approval

Approval for this study was obtained from the Human Investigation Committee of
the Yale University School of Medicine prior to the initiation of the study.

Selection of Patients

The database of the Yale Center for Thoracic Aortic Disease was used to select
patients for the Marfan arm of the study. The database contains 1282 patients with aortic
disease who have been cared for by the section of cardiothoracic surgery at Yale
University School of Medicine. Of these patients, 65 carried a confirmed diagnosis of
Marfan syndrome using the Gent diagnostic criteria. These 65 patients were then crossreferenced with the databases of the department of diagnostic imaging for the availability
of a pre-operative CT scan of the chest without the use of intravenous contrast, resulting
in a total of 8 patients in the Marfan arm. Only pre-operative scans were included in this
study due to concerns about artifact from prosthetic grafts and changes in flow dynamics
which may affect local vessel injury.

For the control arm of the study, the databases of the department of diagnostic
imaging were queried for patients between September, 1998, and February, 1999, and
between September and December, 2000, who had undergone chest CT scanning without
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the use of intravenous contrast. Patients with definite cardiac or aortic pathology were
excluded, as were patients who had undergone prior thoracic surgery. These patients
were then matched with the patients in the Marfan arm of the study for both age at time
of CT scanning and gender. Age matching was conducted by creating categorical ranges
of age as follows: < 30 years old, 31-35 years old, 36-40 years old, and 41-45 years old.
This resulted in 8 control patients.

Evaluation of CT scans

All CT scans were officially interpreted on film or AutoRad by Dr. Coralie Shaw
from the department of diagnostic imaging. The scans were evaluated for the presence of
calcification within the walls of the coronary arteries or the thoracic aorta. The right
coronary artery, left circumflex artery, and the left anterior descending artery were
evaluated separately, with the sum of their individual scores forming the score for the
coronary arteries. Points for calcification were given as follows: 0 points for no calcium,
1 point for minimal flecks (clmm diameter) of calcium on single levels, 2 points for
more than three minimal flecks or larger non-circumferential flecks (l-3mm diameter) on
single or multiple levels, and 3 points for severe (>3mm diameter) flecks or
circumferential calcification. This semi-quantitative scale for calcification has been
described by others (1, 10, 22, 30-31). The total scores possible were 3 points for the
thoracic aorta and 9 points for the coronary arteries (3 from each artery).
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Review of Medical History

The hospital charts of all included patients were thoroughly reviewed for the
presence of the risk factors discussed above which may have confounded the analysis of
arteriosclerosis. Age and gender had already been matched in creating the control arm.
The factors for which the charts were searched include the body mass index (weight in
kilograms divided by height in meters squared) at the time of scanning, as well as history
of hypertension, diabetes mellitus, smoking, and hypercholesterolemia. History of prior
myocardial infarction or stroke was also included in the chart review. History of
hypertension was considered present if the patient had chart documented history of
hypertension at the time of scanning, was taking antihypertensive medication at the time
of scanning, or had a chart documented blood pressure above 140 millimeters of mercury
systolic or 90 millimeters of mercury diastolic on at least two separate occasions (31).
History of diabetes mellitus (DM) was considered present if the patient had chartdocumented history of DM at the time of scanning or was taking insulin or oral
hypoglycemic medication at the time of scanning. History of smoking was considered
present if the patient had chart documented history of current or remote smoking at the
time of scanning. History of hypercholesterolemia was considered present if the patient
had chart documented history of hypercholesterolemia at the time of scanning, was taking
lipid lowering medication at the time of scanning, or had chart documented total
cholesterol above 200 milligrams per deciliter on two fasting serum samples (25).
History of prior myocardial infarction or stroke was considered present if the patient had
chart documented history of these prior events at the time of scanning.
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Data Analysis and Statistical Considerations

The data from the review of patient records and the evaluation of CT scans were
analyzed for significant differences between the two groups. Continuous variables,
including average age, average body mass index, average calcification score in the
thoracic aorta, and average calcification score in the coronary arteries, were evaluated
using the student’s t-test. Since the number of records was relatively small, the
dichotomous variables, which included all other confounders from the patients’ records,
were analyzed using the Fisher exact probability test rather than the Chi-square method.
In all variables, there was one degree of freedom and differences were considered
significant at a p-value less than 0.05. As the number of patients studied in this pilot
study was small, no attempt at multivariate analysis was conducted to determine and
eliminate the influence of the confounding factors on the level of calcification.
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Results

The results of the record review and CT scan evaluation are given as a
compilation of the different patients into averages and total numbers with statistical
results in Table 7. In addition, the data for each patient in each group is given
individually in Table 8.

With regard to confounding factors, age and gender were matched in creating the
control group. However, the average age in the two groups did differ, with the Marfan
group average at 26.6 years and the control group average at 30.5 years. This difference
was not significant (t = 0.850, p = 0.55). For all other confounders, the differences
between the two groups also did not reach statistical significance. The average body
mass index was 21.9 kg/m2 for Marfan patients and 25.6 kg/m2 for control patients (t =
1.02, p = 0.49). There were no patients with hypercholesterolemia or prior myocardial
infarction in either group. Five patients (62.5%) in the Marfan group qualified for
hypertension while only three (37.5%) qualified in the control group (Fisher probability =
0.24). All five of the Marfan patients, however, qualified in this category due to betablocker therapy for aortic dissection prophylaxis, not for classically defined hypertension.
In contrast, all three of the control patients qualified in this category due to chartdocumented elevations in blood pressure in addition to anti-hypertensive therapy. No
patients (0%) had chart-documented diabetes mellitus in the Marfan group, while three
patients (37.5%) had diabetes mellitus in the control group (Fisher probability = 0.1).
Four patients (50%) in the Marfan group and three patients (37.5%) in the control group
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had a history of cigarette smoking (Fisher probability = 0.34). Finally, one patient
(12.5%) in the Marfan group, but no patients (0%) in the control group, had a history of a
minor prior stroke (Fisher probability - 0.5).

The evaluation of CT scans revealed only one patient in the study who had
evident calcification in the thoracic aorta and/or coronary arteries. This control patient
received a calcification score of 1 point for the thoracic aorta and 1 point for the left
anterior descending artery (the left circumflex artery and the right coronary artery were
without calcification). This resulted in an average calcification score of 0.125 for the
control group and an average calcification score of zero for the Marfan group in both the
thoracic aorta and the coronary arteries. These differences were analyzed with the
student’s t-test and found to be not significant, with a p-value of 0.5 in both vessel
distributions.

Age

BMI

HTN

Choi.

DM

Smoker

Marfan

26.6

21.9

5

0

0

4

Control

30.5

25.6

3

0

3

p-value

0.55

0.49

0.24

N/A

0.1

MI

CVA

Coronaries

Aorta

0

1

0

0

3

0

0

0.125

0.125

0.34

N/A

0.5

0.5

0.5

Table 7. Compilation of results for the confounding factors and calcification scores for
each group with results of analysis for statistical analysis. (Abbreviations: Age=average
age at time of CT scan, BMI=average body mass index in kg/m2, HTN=number of
patients with history of hypertension, Chol.=number of patients with history of
hypercholesterolemia, DM=number of patients with history of diabetes mellitus,
Smoker=number of patients with history of cigarette smoking, MI=number of patients
with history of prior myocardial infarction, CVA=number of patients with history of prior
stroke, Coronaries=average calcification score in the coronary arteries, Aorta=average
calcification score in the aorta, p-value=Fisher probability for F1TN, DM, Smoker, and
CVA, and student’s t-test derived p-value for age, BMI, Coronaries, and Aorta)
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Marfan Group
Choi. DM Smoker

MI

CVA

Coronaries

Aorta

+

-

-

0

0

-

-

-

-

0

0

+

-

-

-

-

0

0

29.8

+

-

-

-

+

0

0

42

22.7

-

-

+

-

-

0

0

F

19

18.0

-

-

-

-

-

0

0

7

F

25

23.1

-

-

+

-

-

0

0

8

F

24

27.5

+

-

+

-

-

0

0

Smoker

MI

CVA

Coronaries

Aorta

Patient

Gender

Age

BMI

HTN

1

M

18

15.6

+

-

2

M

32

19.4

+

3

M

17

19.3

4

M

36

5

F

6

Control Group
Patient

Gender

Age

BMI

HTN

Choi.

1

M

23

20.2

-

-

+

-

-

0

0

2

M

32

22.3

-

-

-

-

-

0

0

3

M

16

15.8

-

-

-

-

-

0

0

4

M

40

41.8

+

-

-

-

-

0

0

5

F

45

18.6

+

+

+

-

-

1

1

6

F

28

24.5

+

+

-

-

-

0

0

7

F

30

36.6

-

+

+

-

-

0

0

8

F

30

25.2

-

-

-

-

0

0

-

DM

Table 8. Results of study for individual patients in each group. (Abbreviations:
Age=age at time of CT scan, BMI=body mass index in kg/m2, HTN=history of
hypertension, Chol.=history of hypercholesterolemia, DM=history of diabetes mellitus,
Smoker=history of cigarette smoking, MI=history of prior myocardial infarction,
CVA=history of prior stroke, Coronaries=calcification score in the coronary arteries,
Aorta=calcification score in the aorta)
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Discussion

Conclusions

The results of this study indicate that the Marfan and control groups were not
significantly different in their exposure to the major known risk factors for
arteriosclerosis. The difference in the average levels of CT-detected calcification in the
thoracic aorta and coronary arteries of the patients in these two groups also did not reach
statistical significance. Thus, despite the overwhelming observational trends which led to
the inception of this pilot study, the data from this study do not support the hypothesis
that there is a lower level of arteriosclerosis in patients with Marfan syndrome than in the
general population.

However, this lack of conclusive support for the hypothesis does not indicate that
the hypothesis is false. With only eight patients eligible for each group, this pilot study
has a limited data set which lacks the power to allow for substantial and conclusive
determinations of scientific significance. The small data set creates difficulty in making
valid conclusions for several reasons.

One reason is that the control group cannot be completely matched with the study
group in regards to the confounding factors. Although the statistical analysis revealed an
insignificant difference between the groups for each of the confounding factors, the lack
of power of the analysis could preclude the identification of important differences which

48

may affect the occurrence of calcification in the patients. For example, there are potential
trends in the data which indicate that the patients with Marfan syndrome are younger,
thinner, and less likely to have diabetes mellitus than available controls. Though the
numbers are not significant, the trend is convincing relative to the number of patients in
the study, and could be a potential source for bias in the observations which served as the
impetus for this study. These trends could also potentially become significant with larger
numbers of patients. Also, though the number of patients who qualify as having a history
of hypertension is larger in the Marfan group, in all cases these patients were on betablocker therapy for prevention of aortic dissection. In fact, this risk factor, as defined by
this study and others, may actually be atheroprotective due to the potentially lower blood
pressures of the patients on beta-blocker prophylaxis without classically defined
hypertension.

In addition, only one patient in the study actually had detectable aortic or
coronary calcification on the CT scan. This patient was the oldest patient included in the
study and, as an individual, had several of the risk factors for arteriosclerosis (see Patient
5 under Control Group in Table 8). This fact raises many questions about arterial
calcification. The data presented above from other studies regarding the prevalence of
arterial calcification suggest that more of the patients in this study should have had
calcification present on CT scanning.

One plausible explanation for the lack of results in this study is the young age of
the included patients. With average ages of 26.6 years and 30.5 years in the Marfan and
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control groups, respectively, the population studied may be too young to detect a
substantial amount of calcification. This limitation may be overcome by including older
patients. The difficulty with inclusion of older patients lies in the fact that most Marfan
patients receive operative management of their aortic aneurysms prior to reaching middle
age. In this case, it may be possible to assess post-operative CT scans of Marfan patients
at an older age, with age-matched control subjects, by evaluating calcification in areas of
the aorta and coronary arteries not affected by post-operative changes and artifacts. The
use of post-operative scans would also drastically increase the numbers of patients
studied, since many of the 65 Marfan patients were ineligible for this study due to the
lack of availability of a pre-operative CT scan. This possibility will be discussed in more
detail below in the section on future directions.

Another plausible explanation for the lack of calcification seen in this study is that
a trend is present which is not statistically significant without a larger data set. The
potential does exist that the hypothesis of this study is accurate, and will be proven to be
accurate, with larger, more in-depth studies in the future. The consequences of this
potential finding are remarkable. Arteriosclerosis continues to be a devastating disease
with global epidemiological impact. Any further understanding about arteriosclerosis
that could be gained through knowledge of the interaction of the Marfan vasculature with
the atherosclerotic process would provide great insight into the pathogenesis and
molecular biology of this important disease. This insight could have direct benefits by
providing specific molecular targets for therapy and prevention. In addition, as patients
with Marfan syndrome now survive longer, with nearly normal lifespans, understanding
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of the impact of arteriosclerosis in these patients is becoming paramount. Also, the
possibility that the Marfan syndrome may be atheroprotective has significant
consequences, both in the understanding of arteriosclerosis and in the potential
psychological benefit this finding could provide to patients with the Marfan syndrome.

Future Directions

The limitations of this study provide insight into the potential for future studies,
which may further this research and allow for more meaningful conclusions about the
nature of the relationship between Marfan syndrome and arteriosclerosis. Extensions of
this study have already begun here at Yale. Marfan patients with post-operative films are
also being included, in order to increase the sample size and evaluate older patients in
whom arteriosclerosis may be more detectable. It is probable that these scans will be
useful for the evaluation of calcification and arteriosclerosis despite potential artifact and
flow disturbances. In addition, with the assistance of advertisement through the
publications and website of the National Marfan Foundation, a national pool of Marfan
patients is being recruited for the Arteriosclerosis in Marfan Syndrome (AIMS) study,
which will possess a much larger set of patients from a variety of locations throughout
the United States. It is the hope of the authors that, with the results of these larger
studies, relevant information will be discovered which will provide insight into the
arteriosclerotic process in Marfan patients, provide an important advance in the
knowledge of Marfan syndrome, and help to further the journey towards complete
treatment and prevention of arteriosclerosis.
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